Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000926617-14-000065
Filing Date
2014-11-13
Accepted
2014-11-13 16:15:56
Documents
12
Period of Report
2014-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q c617-20140930x10q.htm 10-Q 817836
2 EX-31.1 c617-20140930ex3119203ba.htm EX-31.1 16322
3 EX-31.2 c617-20140930ex312a63811.htm EX-31.2 16453
4 EX-32.1 c617-20140930ex321e7cdbf.htm EX-32.1 13973
5 GRAPHIC c617-20140930x10qg1.jpg GRAPHIC 18865
6 GRAPHIC c617-20140930x10qg2.jpg GRAPHIC 8009
  Complete submission text file 0000926617-14-000065.txt   2558121

Data Files

Seq Description Document Type Size
7 EX-101.INS c617-20140930.xml EX-101.INS 222598
8 EX-101.SCH c617-20140930.xsd EX-101.SCH 20032
9 EX-101.CAL c617-20140930_cal.xml EX-101.CAL 26600
10 EX-101.DEF c617-20140930_def.xml EX-101.DEF 54714
11 EX-101.LAB c617-20140930_lab.xml EX-101.LAB 162810
12 EX-101.PRE c617-20140930_pre.xml EX-101.PRE 131676
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
VERMILLION, INC. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34810 | Film No.: 141218633
SIC: 2835 In Vitro & In Vivo Diagnostic Substances